Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 31;10(4):e0172422.
doi: 10.1128/spectrum.01724-22. Epub 2022 Jun 27.

In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019

James A Karlowsky  1   2 , Andrew J Walkty  1   2 , Melanie R Baxter  1 , Heather J Adam  1   2 , Philippe R S Lagacé-Wiens  1   2 , Frank Schweizer  1   3 , Denice Bay  1 , Joseph P Lynch 3rd  4 , Michael R Mulvey  1   5 , George G Zhanel  1
Affiliations

In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019

James A Karlowsky et al. Microbiol Spectr. .

Abstract

Cefiderocol was evaluated by broth microdilution versus 1,050 highly antimicrobial-resistant Pseudomonas aeruginosa clinical isolates from the CANWARD study (2007 to 2019). Overall, 98.3% of isolates remained cefiderocol susceptible (MIC, ≤4 μg/mL), including 97.4% of extensively drug-resistant (XDR) (n = 235) and 97.9% of multidrug-resistant (MDR) (n = 771) isolates. Most isolates testing not susceptible to ceftolozane-tazobactam, ceftazidime-avibactam, and imipenem-relebactam remained susceptible to cefiderocol. In vitro data suggest that cefiderocol may be a treatment option for infections caused by MDR and XDR P. aeruginosa. IMPORTANCE After testing cefiderocol against a large collection of clinical isolates of highly antimicrobial-resistant Pseudomonas aeruginosa, we report that cefiderocol is active versus 97.4% of extensively drug-resistant (XDR) and 97.9% of multidrug-resistant (MDR) (n = 771) isolates. These data show that cefiderocol may be a treatment option for infections caused by MDR and XDR P. aeruginosa.

Keywords: antibacterial; bacterial; cephalosporin; susceptibility.

PubMed Disclaimer

Conflict of interest statement

The authors declare a conflict of interest. George G. Zhanel received research funding for this study from Shionogi & Co., Ltd. (Osaka, Japan).

References

    1. Araos R, D’Agata E. 2020. Pseudomonas aeruginosa and other Pseudomonas species, p 2686–2699. In Bennett JE, Dolin R, Blaser MJ (ed), Mandell, Douglas, and Bennett’s principles and practice of infectious diseases, 9th ed. Elsevier, Inc., Philadelphia, PA.
    1. Clinical and Laboratory Standards Institute. 2022. Performance standards for antimicrobial susceptibility testing, 32nd ed. M100. CLSI, Wayne, PA.
    1. Livermore DM. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 34:634–640. doi:10.1086/338782. - DOI - PubMed
    1. Castanheira M, Mills JC, Farrell DJ, Jones RN. 2014. Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals. Antimicrob Agents Chemother 58:6844–6850. doi:10.1128/AAC.03681-14. - DOI - PMC - PubMed
    1. Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam H, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagace-Wiens PR, Walkty A, Noreddin A, Lynch JP, Karlowsky JA. 2019. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multi-drug resistant Gram-negative bacilli. Drugs 79:271–289. doi:10.1007/s40265-019-1055-2. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources